Arsenic Exposure and Subclinical Endpoints of Cardiovascular Disease

Current environmental health reports

Volumn 1, Issue 2, 2014, Pages 148-162

  Wu, Fen ^a   Molinaro, Peter ^b   Chen, Yu ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

Arsenic exposure; Cardiovascular disease; Endothelial dysfunction; Inflammation; Oxidative stress; QTc prolongation; Subclinical atherosclerosis; Susceptibility

Indexed keywords

EID: 84912116932     PISSN: None     EISSN: 21965412     Source Type: Journal    
DOI: 10.1007/s40572-014-0011-2     Document Type: Review

References (116)

1. Nachman KE et al. Arsenic species in poultry feather meal. Sci Total Environ. 2012;417–418:183–8.
2. Wilson D, Hooper C, Shi X. Arsenic and lead in juice: apple, citrus, and apple-base. J Environ Health. 2012;75(5):14–20. quiz 44.
3. Jackson BP et al. Arsenic, organic foods, and brown rice syrup. Environ Health Perspect. 2012;120(5):623–6.
4. Davis MA et al. Rice consumption and urinary arsenic concentrations in U.S. children. Environ Health Perspect. 2012;120(10):1418–24.
5. Gilbert-Diamond D et al. Rice consumption contributes to arsenic exposure in US women. Proc Natl Acad Sci U S A. 2011;108(51):20656–60.
6. Morales KH et al. Risk of internal cancers from arsenic in drinking water. Environ Health Perspect. 2000;108(7):655–61.
7. Chen CJ, Kuo TL, Wu MM. Arsenic and cancers. Lancet. 1988;1(8582):414–5.
8. Chiou HY et al. Incidence of internal cancers and ingested inorganic arsenic: a seven-year follow-up study in Taiwan. Cancer Res. 1995;55(6):1296–300.
9. Argos M et al. A prospective study of arsenic exposure from drinking water and incidence of skin lesions in Bangladesh. Am J Epidemiol. 2011;174(2):185–94.
10. Ahsan H et al. Arsenic exposure from drinking water and risk of premalignant skin lesions in Bangladesh: baseline results from the Health Effects of Arsenic Longitudinal Study. Am J Epidemiol. 2006;163(12):1138–48.
11. Parvez F et al. Nonmalignant respiratory effects of chronic arsenic exposure from drinking water among never-smokers in Bangladesh. Environ Health Perspect. 2008;116(2):190–5.
12. Mazumder DN et al. Arsenic in drinking water and the prevalence of respiratory effects in West Bengal, India. Int J Epidemiol. 2000;29(6):1047–52.
13. Moon K, Guallar E, Navas-Acien A. Arsenic exposure and cardiovascular disease: an updated systematic review. Curr Atheroscler Rep. 2012;14(6):542–55.
14. Chen CJ et al. Increased prevalence of hypertension and long-term arsenic exposure. Hypertension. 1995;25(1):53–60.
15. Rahman M et al. Hypertension and arsenic exposure in Bangladesh. Hypertension. 1999;33(1):74–8.
16. Chen CJ et al. Dose–response relationship between ischemic heart disease mortality and long-term arsenic exposure. Arterioscler Thromb Vasc Biol. 1996;16(4):504–10.
17. Tseng CH et al. Long-term arsenic exposure and ischemic heart disease in arseniasis-hyperendemic villages in Taiwan. Toxicol Lett. 2003;137(1–2):15–21.
18. Yuan Y et al. Acute myocardial infarction mortality in comparison with lung and bladder cancer mortality in arsenic-exposed region II of Chile from 1950 to 2000. Am J Epidemiol. 2007;166(12):1381–91.
19. Chen Y et al. Arsenic exposure from drinking water and mortality from cardiovascular disease in Bangladesh: prospective cohort study. BMJ. 2011;342:d2431.
20. Chen Y et al. A prospective study of arsenic exposure, arsenic methylation capacity, and risk of cardiovascular disease in Bangladesh. Environ Health Perspect. 2013;121(7):832–8.
21. Sohel N et al. Arsenic in drinking water and adult mortality: a population-based cohort study in rural Bangladesh. Epidemiology. 2009;20(6):824–30.
22. Chiou HY et al. Dose–response relationship between prevalence of cerebrovascular disease and ingested inorganic arsenic. Stroke. 1997;28(9):1717–23.
23. Engel RR, Smith AH. Arsenic in drinking water and mortality from vascular disease: an ecologic analysis in 30 counties in the United States. Arch Environ Health. 1994;49(5):418–27.
24. Lewis DR et al. Drinking water arsenic in Utah: a cohort mortality study. Environ Health Perspect. 1999;107(5):359–65.
25. Zierold KM, Knobeloch L, Anderson H. Prevalence of chronic diseases in adults exposed to arsenic-contaminated drinking water. Am J Public Health. 2004;94(11):1936–7.
26. Meliker JR et al. Arsenic in drinking water and cerebrovascular disease, diabetes mellitus, and kidney disease in Michigan: a standardized mortality ratio analysis. Environ Health. 2007;6:4.
27. Medrano MA et al. Arsenic in public water supplies and cardiovascular mortality in Spain. Environ Res. 2010;110(5):448–54.
28. Lisabeth LD et al. Arsenic in drinking water and stroke hospitalizations in Michigan. Stroke. 2010;41(11):2499–504.
29. Moon KA et al. Association between exposure to low to moderate arsenic levels and incident cardiovascular disease: a prospective cohort study. Ann Intern Med. 2013;159(10):649–59. In this large prospective cohort study in American Indians from the Strong Heart Study, arsenic exposure was assessed using the sum of inorganic and methylated arsenic species in urine at baseline. Arsenic exposure at low levels (<100 μg/L) was associated with increased risks of incident fatal and nonfatal cardiovascular disease, coronary heart disease, and stroke.
30. Barchowsky A et al. Stimulation of reactive oxygen, but not reactive nitrogen species, in vascular endothelial cells exposed to low levels of arsenite. Free Radic Biol Med. 1999;27(11–12):1405–12.
31. Chen YC, Lin-Shiau SY, Lin JK. Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis. J Cell Physiol. 1998;177(2):324–33.
32. Maiti S, Chatterjee AK. Differential response of cellular antioxidant mechanism of liver and kidney to arsenic exposure and its relation to dietary protein deficiency. Environ Toxicol Pharmacol. 2000;8(4):227–35.
33. Santra A et al. Hepatic damage caused by chronic arsenic toxicity in experimental animals. J Toxicol Clin Toxicol. 2000;38(4):395–405.
34. Kotyzova D, Bludovska M, Eybl V. Differential influences of various arsenic compounds on antioxidant defense system in liver and kidney of rats. Environ Toxicol Pharmacol. 2013;36(3):1015–21.
35. Straub AC et al. Arsenic-stimulated liver sinusoidal capillarization in mice requires NADPH oxidase-generated superoxide. J Clin Invest. 2008;118(12):3980–9.
36. Bunderson M, Coffin JD, Beall HD. Arsenic induces peroxynitrite generation and cyclooxygenase-2 protein expression in aortic endothelial cells: possible role in atherosclerosis. Toxicol Appl Pharmacol. 2002;184(1):11–8.
37. Bunderson M et al. Arsenic exposure exacerbates atherosclerotic plaque formation and increases nitrotyrosine and leukotriene biosynthesis. Toxicol Appl Pharmacol. 2004;201(1):32–9.
38. Wu MM et al. Gene expression of inflammatory molecules in circulating lymphocytes from arsenic-exposed human subjects. Environ Health Perspect. 2003;111(11):1429–38.
39. Tsai SH et al. Arsenite stimulates cyclooxygenase-2 expression through activating IkappaB kinase and nuclear factor kappaB in primary and ECV304 endothelial cells. J Cell Biochem. 2002;84(4):750–8.
40. Srivastava S et al. Arsenic exacerbates atherosclerotic lesion formation and inflammation in ApoE-/- mice. Toxicol Appl Pharmacol. 2009;241(1):90–100.
41. Padovani AM, Molina MF, Mann KK. Inhibition of liver x receptor/retinoid X receptor-mediated transcription contributes to the proatherogenic effects of arsenic in macrophages in vitro. Arterioscler Thromb Vasc Biol. 2010;30(6):1228–36.
42. Kumagai Y, Pi J. Molecular basis for arsenic-induced alteration in nitric oxide production and oxidative stress: implication of endothelial dysfunction. Toxicol Appl Pharmacol. 2004;198(3):450–7.
43. Balakumar P, Kaur J. Arsenic exposure and cardiovascular disorders: an overview. Cardiovasc Toxicol. 2009;9(4):169–76.
44. Navas-Acien A et al. Arsenic exposure and cardiovascular disease: a systematic review of the epidemiologic evidence. Am J Epidemiol. 2005;162(11):1037–49.
45. Navas-Acien A et al. Arsenic exposure and type 2 diabetes: a systematic review of the experimental and epidemiological evidence. Environ Health Perspect. 2006;114(5):641–8.
46. Abhyankar LN et al. Arsenic exposure and hypertension: a systematic review. Environ Health Perspect. 2012;120(4):494–500.
47. Lorenz MW et al. Prediction of clinical cardiovascular events with carotid intima-media thickness—a systematic review and meta-analysis. Circulation. 2007;115(4):459–67.
48. Stein JH, Korcarz CE, Hurst RT. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American society of Echocardiography carotid intima-media thickness task force (vol 21, pg 93, 2008). J Am Soc Echocardiogr. 2008;21(4):376.
49. Greenland P et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2010;122(25):e584–636.
50. Wang CH et al. Biological gradient between long-term arsenic exposure and carotid atherosclerosis. Circulation. 2002;105(15):1804–9. This ecological study from southwestern Taiwan used the median level of well-water arsenic in a village where the participants resided and found a dose–response relationship between high levels of arsenic exposure (700–930 μg/L) and carotid atherosclerosis, defined based on carotid artery intima-media thickness and carotid plaque.
51. Wu MM et al. Effect of plasma homocysteine level and urinary monomethylarsonic acid on the risk of arsenic-associated carotid atherosclerosis. Toxicol Appl Pharmacol. 2006;216(1):168–75.
52. Chen Y et al. Arsenic exposure from drinking-water and carotid artery intima-medial thickness in healthy young adults in Bangladesh. J Health Popul Nutr. 2006;24(2):253–7.
53. Holaj R et al. Intima-media thickness of the common carotid artery is the significant predictor of angiographically proven coronary artery disease. Can J Cardiol. 2003;19(6):670–6.
54. Chen Y et al. Arsenic exposure from drinking water, arsenic methylation capacity, and carotid intima-media thickness in Bangladesh. Am J Epidemiol. 2013;178(3):372–81. In this cross-sectional study nested in the HEALS from Bangladesh, in which >90 % of participants have been exposed to arsenic levels of 0.1–300 μg/L, there was a positive association between arsenic exposure measured at the individual level through well water and urine samples at baseline and cIMT measured on average 7 years later.
55. Osorio-Yanez C et al. Carotid intima-media thickness and plasma asymmetric dimethylarginine in Mexican children exposed to inorganic arsenic. Environ Health Perspect. 2013;121(9):1090–6.
56. Algra A et al. QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest. Circulation. 1991;83(6):1888–94.
57. Goldberg RJ et al. Duration of the QT interval and total and cardiovascular mortality in healthy persons (The Framingham Heart Study experience). Am J Cardiol. 1991;67(1):55–8.
58. Okin PM et al. Assessment of QT interval and QT dispersion for prediction of all-cause and cardiovascular mortality in American Indians: the Strong Heart Study. Circulation. 2000;101(1):61–6.
59. Ahmad SA et al. Electrocardiographic abnormalities among arsenic-exposed persons through groundwater in Bangladesh. J Health Popul Nutr. 2006;24(2):221–7.
60. Yildiz A et al. Effect of chronic arsenic exposure from drinking waters on the QT interval and transmural dispersion of repolarization. J Int Med Res. 2008;36(3):471–8.
61. Mumford JL et al. Chronic arsenic exposure and cardiac repolarization abnormalities with QT interval prolongation in a population-based study. Environ Health Perspect. 2007;115(5):690–4. This is the first study from Inner Mongolia that evaluated the effect of low-to-moderate levels of arsenic exposure on QTc prolongation and found a monotonic relationship between well-water arsenic measured at the household level and QTc prolongation. However, the exposure categories were wide (≤21, 100–300, 430–690 μg/L).
62. Wang CH et al. Increased risk of QT prolongation associated with atherosclerotic diseases in arseniasis-endemic area in southwestern coast of Taiwan. Toxicol Appl Pharmacol. 2009;239(3):320–4.
63. Mordukhovich I et al. Association between low-level environmental arsenic exposure and QT interval duration in a general population study. Am J Epidemiol. 2009;170(6):739–46.
64. Chen Y et al. Arsenic exposure from drinking water and QT-interval prolongation: results from the Health Effects of Arsenic Longitudinal Study. Environ Health Perspect. 2013;121(4):427–32, 432e1-7. The most recent large study nested in the HEALS that found a positive association between arsenic exposure and QTc prolongation, especially among women.
65. Wang CH et al. Arsenic-induced QT dispersion is associated with atherosclerotic diseases and predicts long-term cardiovascular mortality in subjects with previous exposure to arsenic: a 17-year follow-up study. Cardiovasc Toxicol. 2010;10(1):17–26.
66. Adams DH, Shaw S. Leucocyte-endothelial interactions and regulation of leucocyte migration. Lancet. 1994;343(8901):831–6.
67. Blankenberg S et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation. 2001;104(12):1336–42.
68. Hwang SJ et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation. 1997;96(12):4219–25.
69. Ridker PM et al. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet. 1998;351(9096):88–92.
70. Chen Y et al. Association between arsenic exposure from drinking water and plasma levels of soluble cell adhesion molecules. Environ Health Perspect. 2007;115(10):1415–20.
71. Wu F et al. Association between arsenic exposure from drinking water and plasma levels of cardiovascular markers. Am J Epidemiol. 2012;175(12):1252–61. This cross-sectional study nested in the HEALS assessed the relation between arsenic exposure and plasma levels of six biomarkers of systemic inflammation and endothelial dysfunction and found a positive association of well-water arsenic and total urinary arsneic with plasma levels of soluble vascular adhesion molecule-1.
72. Karim MR et al. Increases in oxidized low-density lipoprotein and other inflammatory and adhesion molecules with a concomitant decrease in high-density lipoprotein in the individuals exposed to arsenic in Bangladesh. Toxicol Sci. 2013;135(1):17–25.
73. Steinberg D. Role of oxidized LDL and antioxidants in atherosclerosis. Adv Exp Med Biol. 1995;369:39–48.
74. Heinecke JW. Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low density lipoprotein hypothesis. Atherosclerosis. 1998;141(1):1–15.
75. Holvoet P et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 2001;21(5):844–8.
76. Tsimikas S et al. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study. J Am Coll Cardiol. 2006;47(11):2219–28.
77. Meisinger C et al. Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation. 2005;112(5):651–7.
78. Wadham C et al. High-density lipoproteins neutralize C-reactive protein proinflammatory activity. Circulation. 2004;109(17):2116–22.
79. Soucy NV et al. Neovascularization and angiogenic gene expression following chronic arsenic exposure in mice. Cardiovasc Toxicol. 2005;5(1):29–41.
80. Vaughan DE. PAI-1 and atherothrombosis. J Thromb Haemost. 2005;3(8):1879–83.
81. Galis ZS et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94(6):2493–503.
82. Zhang R et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA. 2001;286(17):2136–42.
83. Meuwese MC et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol. 2007;50(2):159–65.
84. Hansson J et al. Biomarkers of extracellular matrix metabolism (MMP-9 and TIMP-1) and risk of stroke, myocardial infarction, and cause-specific mortality: cohort study. PLoS One. 2011;6(1):e16185.
85. Banerjee M et al. Evaluation of the serum catalase and myeloperoxidase activities in chronic arsenic-exposed individuals and concomitant cytogenetic damage. Toxicol Appl Pharmacol. 2010;249(1):47–54.
86. Tseng CH et al. Lipid profile and peripheral vascular disease in arseniasis-hyperendemic villages in Taiwan. Angiology. 1997;48(4):321–35.
87. Nabi AH, Rahman MM, Islam LN. Evaluation of biochemical changes in chronic arsenic poisoning among Bangladeshi patients. Int J Environ Res Public Health. 2005;2(3–4):385–93.
88. Hsueh YM et al. Low serum carotene level and increased risk of ischemic heart disease related to long-term arsenic exposure. Atherosclerosis. 1998;141(2):249–57.
89. Yu RC et al. Arsenic methylation capacity and skin cancer. Cancer Epidemiol Biomarkers Prev. 2000;9(11):1259–62.
90. Chen YC et al. Arsenic methylation and skin cancer risk in southwestern Taiwan. J Occup Environ Med. 2003;45(3):241–8.
91. Tseng CH et al. Long-term arsenic exposure and incidence of non-insulin-dependent diabetes mellitus: a cohort study in arseniasis-hyperendemic villages in Taiwan. Environ Health Perspect. 2000;108(9):847–51.
92. Parvez F et al. A prospective study of respiratory symptoms associated with chronic arsenic exposure in Bangladesh: findings from the Health Effects of Arsenic Longitudinal Study (HEALS). Thorax. 2010;65(6):528–33.
93. Ahsan H et al. Arsenic metabolism, genetic susceptibility, and risk of premalignant skin lesions in Bangladesh. Cancer Epidemiol Biomarkers Prev. 2007;16(6):1270–8.
94. Wu F et al. Interaction between arsenic exposure from drinking water and genetic susceptibility in cardiovascular disease risk in Bangladesh. Submitted. 2013.
95. Hsieh YC et al. Risk of carotid atherosclerosis associated with genetic polymorphisms of apolipoprotein E and inflammatory genes among arsenic exposed residents in Taiwan. Toxicol Appl Pharmacol. 2008;227(1):1–7.
96. Hsueh YM et al. Genetic polymorphisms of oxidative and antioxidant enzymes and arsenic-related hypertension. J Toxicol Environ Health A. 2005;68(17–18):1471–84.
97. Wu MM et al. GT-repeat polymorphism in the heme oxygenase-1 gene promoter and the risk of carotid atherosclerosis related to arsenic exposure. J Biomed Sci. 2010;17:70.
98. Hsieh YC et al. Significantly increased risk of carotid atherosclerosis with arsenic exposure and polymorphisms in arsenic metabolism genes. Environ Res. 2011;111(6):804–10.
99. Wang YH et al. Effects of arsenic exposure and genetic polymorphisms of p53, glutathione S-transferase M1, T1, and P1 on the risk of carotid atherosclerosis in Taiwan. Atherosclerosis. 2007;192(2):305–12.
100. Wu F et al. Interaction between arsenic exposure from drinking water and genetic susceptibility in carotid intima-media thickness in Bangladesh. Toxicol Appl Pharmacol. 2014; pii: S0041–008X(14)00059-3. doi:10.1016/j.taap.2014.02.014.
101. Pierce BL et al. Genome-wide association study identifies chromosome 10q24.32 variants associated with arsenic metabolism and toxicity phenotypes in Bangladesh. PLoS Genet. 2012;8(2):e1002522.
102. Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol. 1997;17(11):2309–15.
103. Ramos O et al. Arsenic increased lipid peroxidation in rat tissues by a mechanism independent of glutathione levels. Environ Health Perspect. 1995;103 Suppl 1:85–8.
104. Han SG, Castranova V, Vallyathan V. Heat shock protein 70 as an indicator of early lung injury caused by exposure to arsenic. Mol Cell Biochem. 2005;277(1–2):153–64.
105. Balagopal PB et al. Nontraditional risk factors and biomarkers for cardiovascular disease: mechanistic, research, and clinical considerations for youth: a scientific statement from the American Heart Association. Circulation. 2011;123(23):2749–69.
106. Klei LR, Garciafigueroa DY, Barchowsky A. Arsenic activates endothelin-1 Gi protein-coupled receptor signaling to inhibit stem cell differentiation in adipogenesis. Toxicol Sci. 2013;131(2):512–20.
107. Garciafigueroa DY et al. Arsenic-stimulated lipolysis and adipose remodeling is mediated by G-protein-coupled receptors. Toxicol Sci. 2013;134(2):335–44.
108. Kurzius-Spencer M et al. Contribution of diet to aggregate arsenic exposures—an analysis across populations. J Expo Sci Environ Epidemiol. 2013.
109. Farzan SF, Karagas MR, Chen Y. In utero and early life arsenic exposure in relation to long-term health and disease. Toxicol Appl Pharmacol. 2013;272(2):384–90.
110. Whitlock G et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373(9669):1083–96.
111. Ben-Shlomo Y, Kuh D. A life course approach to chronic disease epidemiology: conceptual models, empirical challenges and interdisciplinary perspectives. Int J Epidemiol. 2002;31(2):285–93.
112. Lynch J, Smith GD. A life course approach to chronic disease epidemiology. Annu Rev Public Health. 2005;26:1–35.
113. Pinyayev TS et al. Preabsorptive metabolism of sodium arsenate by anaerobic microbiota of mouse cecum forms a variety of methylated and thiolated arsenicals. Chem Res Toxicol. 2011;24(4):475–7.
114. Van de Wiele T et al. Arsenic metabolism by human gut microbiota upon in vitro digestion of contaminated soils. Environ Health Perspect. 2010;118(7):1004–9.
115. United States Environmental Protection Agency. Fact sheet: drinking water standard for arsenic. EPA 815-F-00-015. Available: http://www.epa.gov/safewater/arsenic/regulations_factsheet.html Accessed 6 March 2012.
116. WHO (World Health Organization). Guidelines for Drinking-water Quality: Incorporating First and Second Addenda to Third Edition. Vol. 1—Recommendations. Geneva: WHO Press. Available: http://www.who.int/water_sanitation_health/dwq/gdwq3/en/index.html Accessed 1 October 2012.